These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8133004)

  • 21. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
    Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles mumps rubella (MMR) vaccine in Japan.
    Kuno-Sakai H; Kimura M
    Acta Paediatr Jpn; 1988 Apr; 30(2):167-74. PubMed ID: 3149851
    [No Abstract]   [Full Text] [Related]  

  • 23. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [35-year measles, mumps, rubella vaccination assessment in France].
    Reinert P; Soubeyrand B; Gauchoux R
    Arch Pediatr; 2003 Nov; 10(11):948-54. PubMed ID: 14613687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel measles outbreak control strategy in the Netherlands in 2013-2014 using a national electronic immunization register: A study of early MMR uptake and its determinants.
    Nic Lochlainn LM; Woudenberg T; van Lier A; Zonnenberg I; Philippi M; de Melker HE; Hahné SJM
    Vaccine; 2017 Oct; 35(43):5828-5834. PubMed ID: 28923422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous administration of a diphtheria and tetanus toxoids and acellular pertussis vaccine with measles-mumps-rubella and oral poliovirus vaccines.
    Rothstein EP; Bernstein HH; Glode MP; Laussucq S; Nonenmacher J; Long SS; Hackell JG
    Am J Dis Child; 1993 Aug; 147(8):854-7. PubMed ID: 8394646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do HIV-positive adult immigrants need to be screened for measles-mumps-rubella and varicella zoster virus immunization?
    Llenas-García J; Rubio R; Hernando A; Arrazola P; Pulido F
    AIDS Care; 2013 Aug; 25(8):980-9. PubMed ID: 23244745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events following measles-mumps-rubella and measles vaccinations in college students.
    Chen RT; Moses JM; Markowitz LE; Orenstein WA
    Vaccine; 1991 May; 9(5):297-9. PubMed ID: 1872012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children.
    Palumbo P; Hoyt L; Demasio K; Oleske J; Connor E
    Pediatr Infect Dis J; 1992 Dec; 11(12):1008-14. PubMed ID: 1461690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles immunity in employees of a multihospital healthcare provider.
    Wright LJ; Carlquist JF
    Infect Control Hosp Epidemiol; 1994 Jan; 15(1):8-11. PubMed ID: 8133012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measles immunization of 2-year-olds in a rural southern state.
    Feldman S; Andrew M; Gilbert J; Bracken B; Thompson FE
    JAMA; 1994 May; 271(18):1417-20. PubMed ID: 8176803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
    Singh R; John TJ; Cherian T; Raghupathy P
    Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomised single blind trial of a combined mumps measles rubella vaccine to evaluate serological response and reactions in the UK population.
    Edees S; Pullan CR; Hull D
    Public Health; 1991 Mar; 105(2):91-7. PubMed ID: 2068243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.